Daewoong Pharmaceutical Co. Ltd.

This trial is testing an experimental drug called DWP14012 to see if it can prevent erosive esophagitis—a condition where stomach acid damages the esophagus—from coming back after it has healed. About 420 adults aged 19 to 75 with healed erosive esophagitis will take either DWP14…

This phase 3 trial tests whether an experimental drug called DWP14012 (fexuprazan) can heal stomach ulcers as well as or better than the standard treatment lansoprazole. About 384 adults with at least one active gastric ulcer will receive either DWP14012 or lansoprazole daily for…

This study tests whether starting treatment with two experimental drugs together (DWP16001 and DWC202518) works better than either drug alone for people with type 2 diabetes. About 510 adults will take the combo or a single drug for 24 weeks, and researchers will measure changes …

This study will follow 12,000 Korean adults with dyslipidemia (high cholesterol) who are prescribed Baroezet Tablet by their doctor. Researchers will measure changes in LDL ("bad") cholesterol and other fats in the blood over 24 weeks, and track any side effects. The goal is to s…

This phase 4 trial will test the drug apremilast in 425 adults with moderate-to-severe psoriasis. Over 32 weeks, researchers will measure how well the drug clears skin patches and monitor for side effects. The goal is to confirm apremilast's effectiveness and safety in a real-wor…

This study looks at whether the drug Fexuclue can prevent stomach ulcers in people who need to take NSAID pain relievers long-term. About 7,000 adults in Korea will take Fexuclue and report their stomach symptoms over 4 weeks. The goal is to see if the drug reduces ulcer symptoms…

This study tests whether a new medicine called Fexuprazan (Fexuclue) can prevent stomach ulcers caused by NSAID painkillers like ibuprofen. About 360 adults with joint or muscle pain who need daily NSAIDs will take either Fexuprazan or an older drug (Lansoprazole) for 24 weeks. T…

This study tests two nasal protective devices (Noseguard and Noseguard Night) in 2000 adults to see if they can reduce the risk of catching respiratory infections like COVID-19 and influenza. Participants will use the devices as directed for 8 weeks, and researchers will track in…